It is widely thought that Adalimumab may mitigate the high level of TNF-α in rheumatoid arthritis patients, resulting in hair repigmentation, but the underlying mechanism warrants further research (Fig. 2). The gene discussed is TNF; the disease is rheumatoid arthritis.